

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)



(10) International Publication Number
WO 2022/129609 A3

(51) International Patent Classification:

C07K 14/005 (2006.01) C07K 16/00 (2006.01)

A61P 25/00 (2006.01) C12N 15/86 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/086645

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

17 December 2021 (17.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20215823.4 18 December 2020 (18.12.2020) EP

(88) Date of publication of the international search report:

15 September 2022 (15.09.2022)

(71) Applicant: AC IMMUNE SA [CH/CH]; EPFL Innovation Park, Building B, 1015 Lausanne (CH).

(72) Inventors: DE VAL, Gregorio; c/o AC IMMUNE SA, EPFL Innovation Park, Building B, 1015 Lausanne (CH).
NÉVOLTRIS, Damien; c/o AC IMMUNE SA, EPFL Innovation Park, Building B, 1015 Lausanne (CH).

(74) Agent: BOULT WADE TENNANT LLP; Salisbury Square House, 8 Salisbury Square, London EC4Y 8AP (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: ANTIBODY DELIVERY

(57) Abstract: A vector comprises a polynucleotide encoding an antibody or antibody fragment for use in a method of treatment of a disease or disorder of the central nervous system (CNS) in a subject, wherein the vector transduces or transfects cells of the blood brain barrier (BBB) and the transduced or transfected BBB cells express the antibody or antibody fragment resulting in delivery of the antibody or antibody fragment into the CNS, preferably into the brain parenchyma. Expression cassettes useful in such vectors may comprise from 5' to 3': at least one promoter operably linked to a first gene encoding a light chain of an antibody or antibody fragment and to a second gene encoding a heavy chain of the antibody or antibody fragment and further comprise an IRES after the first gene encoding the light chain of the antibody or antibody fragment and before the second gene encoding the heavy chain of the antibody or antibody fragment or a first promoter operably linked to a first gene encoding a light chain of an antibody or antibody fragment and a second promoter operably linked to a second gene encoding a heavy chain of the antibody or antibody fragment. The antibodies and antibody fragments thus produced may be of higher quality, displaying lower levels of aggregation and unwanted immunogenicity.



WO 2022/129609 A3